Lisinopril Safety in Complete Heart Block with Transvenous Pacemaker
Yes, lisinopril is safe to use in a patient with complete heart block who has a functioning transvenous pacemaker. The pacemaker eliminates the primary concern about ACE inhibitors in complete heart block—namely, the risk of worsening bradycardia or suppressing escape rhythms.
Key Reasoning
Why the Pacemaker Changes Everything
The ACC/AHA guidelines explicitly identify that one factor influencing pacemaker decision-making is the "necessity for administering medication that might depress escape heart rates or aggravate atrioventricular (AV) block" 1, 2, 1. This consideration becomes irrelevant once a permanent pacemaker is in place, as the device maintains adequate heart rate regardless of the underlying conduction system.
The guidelines specifically note that complete heart block with "ectopic rhythms and drugs that suppress the automaticity of escape pacemakers and result in symptomatic bradycardia" is a Class I indication for permanent pacing 2. Once the pacemaker is implanted and functioning properly, this concern is addressed.
Lisinopril's Cardiac Effects
Lisinopril does not directly affect cardiac conduction or worsen AV block. The FDA label for lisinopril does not list heart block, bradycardia, or conduction abnormalities as contraindications or warnings 3. The primary cardiovascular concerns with lisinopril are:
- Hypotension (especially in volume-depleted patients or those with systolic BP <100 mmHg)
- Renal dysfunction (particularly in patients dependent on renin-angiotensin system activity)
- Hyperkalemia (especially with renal insufficiency or concurrent potassium-sparing agents)
None of these directly relate to the presence of complete heart block or pacemaker function 3.
Clinical Evidence in Heart Failure
Extensive clinical trial data demonstrates lisinopril's safety and efficacy in heart failure patients, many of whom had pacemakers. The ATLAS study evaluated over 3,000 patients with systolic heart failure, comparing high-dose (32.5-35 mg) versus low-dose (2.5-5 mg) lisinopril 4. High-dose lisinopril showed:
- 12% lower risk of death or hospitalization (p=0.002)
- 24% fewer heart failure hospitalizations (p=0.002)
- Similar adverse event profiles between dose groups
Multiple studies confirm lisinopril is well-tolerated in heart failure patients receiving digoxin and diuretics, with the most common adverse events being dizziness, headache, hypotension, and diarrhea—not conduction abnormalities 4, 5, 6, 7, 8.
Practical Management Considerations
Monitor These Parameters
- Blood pressure: Start low and titrate carefully if systolic BP <100 mmHg or patient has volume depletion 3
- Renal function: Check creatinine and BUN periodically, especially if patient has pre-existing renal impairment 3
- Potassium levels: Monitor for hyperkalemia, particularly with concurrent diuretics or renal dysfunction 3
- Pacemaker function: Ensure device is functioning properly with adequate capture and sensing
Common Pitfalls to Avoid
- Do not withhold lisinopril solely because of complete heart block if the pacemaker is functioning properly
- Do not confuse AV block with hypotension risk—these are separate issues
- Avoid starting lisinopril in hemodynamically unstable patients (systolic BP <80 mmHg, signs of hypoperfusion) 3
- Be cautious in post-MI patients with complete heart block, as the FDA label notes to avoid lisinopril in hemodynamically unstable patients after acute MI 3
Dosing Strategy
Start with low doses (2.5-5 mg daily) and titrate based on blood pressure tolerance and renal function, not based on the presence of the pacemaker 3. The 2009 ACC/AHA heart failure guidelines note that even low doses of ACE inhibitors provide important benefits, and patients with advanced disease may only tolerate small doses 9.
The presence of a functioning transvenous pacemaker removes the conduction-related contraindication to ACE inhibitor therapy. Focus your monitoring on the standard ACE inhibitor concerns: hypotension, renal function, and hyperkalemia.